Internal Medicine, Pulmonary Disease · Chesterfield, MO
NPI
1538340930
Since 2007
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
222 S Woods Mill Rd
Chesterfield, MO, 63017
Phone (314) 576-6700
Groups this clinician bills Medicare through
Medicare paid, 2024
$205K
3,697 services
Medicare patients, 2024
1,049
Average age 77
Drug cost, 2024
$2.9M
5,339 prescriptions
Company payments, 2025
$42K
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Bobby Shah was code 99213 (office e&m - established), 733 times for 485 patients. In total Bobby Shah billed 3,697 services in 36 codes, and Medicare paid $205K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-02-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 733 | 485 | $62.35 | $46K |
| 99232 Hospital E&M - Subsequent | Facility | 564 | 193 | $60.36 | $34K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 402 | 250 | $12.10 | $4,863 |
| 99214 Office E&M - Established | Office | 309 | 233 | $89.68 | $28K |
| 99231 Hospital E&M - Subsequent | Facility | 188 | 119 | $37.88 | $7,121 |
| 99223 Hospital E&M - Initial | Facility | 179 | 157 | $132.09 | $24K |
| 94726 Pulmonary Function Testing | Facility | 157 | 155 | $9.03 | $1,418 |
| 94729 Pulmonary Function Testing | Facility | 155 | 153 | $6.71 | $1,041 |
| 94010 Pulmonary Function Testing | Office | 148 | 146 | $18.98 | $2,810 |
| 99215 Office E&M - Established | Office | 124 | 59 | $129.82 | $16K |
| 99204 Office E&M - New | Office | 117 | 117 | $122.95 | $14K |
| 94060 Pulmonary Function Testing | Facility | 97 | 95 | $7.74 | $750 |
| 94010 Pulmonary Function Testing | Facility | 80 | 80 | $6.18 | $495 |
| 99233 Hospital E&M - Subsequent | Facility | 68 | 23 | $90.96 | $6,185 |
| 99203 Office E&M - New | Office | 64 | 64 | $73.56 | $4,708 |
By year: 2022 $242K for 3,731 services; 2023 $224K for 3,445 services; 2024 $205K for 3,697 services.
Medicare prescription drug claims, 2024
In 2024, the drug Bobby Shah prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 901 prescriptions and refills. In total Bobby Shah wrote 5,339 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 901 | 1,240 | 189 | $788K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 684 | 811 | 286 | $15K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 616 | 795 | 140 | $365K |
| Breo Ellipta Fluticasone/Vilanterol | 397 | 518 | 91 | $202K |
| Prednisone Generic | 331 | 460 | 140 | $1,790 |
| Azithromycin Generic | 290 | 413 | 72 | $4,084 |
| Montelukast Sodium Generic | 202 | 527 | 60 | $1,993 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 161 | 243 | 44 | $21K |
| Ipratropium Bromide Generic | 154 | 177 | 51 | $3,241 |
| Symbicort Budesonide/Formoterol Fumarate | 119 | 169 | 34 | $39K |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 114 | 162 | 35 | $27K |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 106 | 179 | 31 | $109K |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | 102 | 156 | 23 | $73K |
| Roflumilast Generic | 93 | 142 | 22 | $12K |
| Eliquis Apixaban | 82 | 166 | 24 | $97K |
Brand drugs: 3,279 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Bobby Shah $42K ($42K in general payments such as food, travel and fees) from 25 companies. The largest payer was Genzyme Corporation with $29K.
| Company | Payments | Amount |
|---|---|---|
| Genzyme Corporation SNY | 28 | $29K |
| GlaxoSmithKline, LLC. GSK | 42 | $9,809 |
| Verona Pharma, Inc. VRNA | 5 | $1,550 |
| AstraZeneca Pharmaceuticals LP AZN | 24 | $620 |
| Merck Sharp & Dohme LLC MRK | 6 | $140 |
| Actelion Pharmaceuticals US, Inc. JNJ | 5 | $130 |
| Tactile Systems Technology Inc TCMD | 3 | $104 |
| Insmed, Inc. INSM | 6 | $99.85 |
| Regeneron Healthcare Solutions, Inc. REGN | 4 | $92.92 |
| Viatris Specialty LLC | 5 | $91.86 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.